<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ren Fail</journal-id><journal-id journal-id-type="iso-abbrev">Ren Fail</journal-id><journal-title-group><journal-title>Renal Failure</journal-title></journal-title-group><issn pub-type="ppub">0886-022X</issn><issn pub-type="epub">1525-6049</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39011577</article-id><article-id pub-id-type="pmc">PMC467103</article-id>
<article-id pub-id-type="doi">10.1080/0886022X.2024.2376331</article-id><article-id pub-id-type="publisher-id">2376331</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Hemodialysis and Peritoneal Dialysis</subject></subj-group></article-categories><title-group><article-title>Effect of different exit-site care dressings on preventing peritoneal dialysis related infection from nontropical area: a systematic review and network meta-analysis</article-title><alt-title alt-title-type="left-running-head">C. Feng et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Chunyan</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AUFN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yue</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AUFN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Weiyi</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AUFN2" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Mengyuan</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AUFN2" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1527-8852</contrib-id><name><surname>Su</surname><given-names>Chun-Yan</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AN0001" ref-type="corresp"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Nephrology, Peking University Third Hospital</institution>, <city>Beijing</city>, <country>China</country></aff><aff id="AF0002"><label>b</label><institution>Department of Interventional Radiology and Vascular Surgery, Peking University Third Hospital</institution>, <city>Beijing</city>, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><label>*</label><p>These authors have contributed equally to this work and share first authorship</p></fn><fn id="AUFN2"><label>#</label><p>Co-authors</p></fn><fn id="AUFN3"><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">https://doi.org/10.1080/0886022X.2024.2376331</ext-link>.</p></fn><corresp id="AN0001">CONTACT Chun-Yan Su <email xlink:href="mailto:scybmu@126.com">scybmu@126.com</email>
<institution>Department of Nephrology, Peking University Third Hospital</institution>, <addr-line>No.49 North Garden Rd, Haidian Dist.</addr-line>, <city>Beijing</city>
<postal-code>100191</postal-code>, <country>China</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>7</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>7</month><year>2024</year></pub-date><volume>46</volume><issue>2</issue><elocation-id>2376331</elocation-id><pub-history><event event-type="received"><date><day>23</day><month>1</month><year>2024</year></date></event><event event-type="revised"><date><day>20</day><month>6</month><year>2024</year></date></event><event event-type="accepted"><date><day>30</day><month>6</month><year>2024</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>12</day><month>7</month><year>2024</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>12</day><month>7</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IRNF_46_2376331.pdf"/><abstract><title>Abstract</title><sec><title>Object</title><p>This study aims to conduct a systematic review and network meta-analysis to comprehensively evaluate the efficacy of various dressings in preventing exit-site infection (ESI) and peritonitis.</p></sec><sec><title>Methods</title><p>We searched PubMed, Embase, Web of Science, CINAHL Plus with Full Text (EBSCO), Sino Med, Wan Fang Data, China National Knowledge Infrastructure (CNKI) from 1 January 1999 to 10 July 2023. The language restrictions were Chinese and English. Randomized controlled trials, non-randomized controlled trials, and self-controlled trials were included in this study. We used ROB 2 tool to evaluate the quality of the included literature. Two authors independently extracted the data according to the Cochrane Handbook. A Frequentist network meta-analysis was performed using Stata17.0 according to PRISAMA with a random effects model.</p></sec><sec><title>Results</title><p>From 2092 potentially eligible studies, thirteen studies were selected for analysis, including nine randomized controlled studies, three quasi-experimental studies and one self-controlled trial. A total of 1229 patients were included to compare five types of exit site care dressings, named disinfection dressings, antibacterial dressings, non-antibacterial occlusive dressings, sterile gauze, and no-particular dressings. The outcome of prevention ESI is antibacterial dressings (SUCRA = 97.6) &#x0003e;non-antibacterial occlusive dressings (SUCRA = 68.3) &#x0003e;disinfection dressings (SUCRA = 50.6) &#x0003e;no-particular dressings (SUCRA = 23.9) &#x0003e;sterile gauze (SUCRA = 9.5). The antibacterial dressings were more effective than sterile gauze (OR = 0.13, 95%CI 0.04&#x0223c;0.44), and no-particular dressing (OR = 0.18, 95%CI 0.07&#x0223c;0.50) in preventing ESI; the non-antibacterial occlusive dressings were effective than sterile gauze (OR:0.30, 95%CI 0.16&#x0223c;0.57). There is no statistical significance between no-particular dressings and other types of dressings in preventing the mature ESI. There is no statistical significance in the effectiveness of five types of dressings in preventing peritonitis.</p></sec><sec><title>Conclusions</title><p>The no-particular dressings maybe more cost-effective for preventing mature ESI. None of the dressings was more effective than another in preventing peritonitis. Then, none of the different types of dressing is strongly recommended for preventing ESI or peritonitis.</p></sec><sec><p><bold>Registration</bold>CRD42022366756</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Exit-site infection</kwd><kwd>peritoneal dialysis</kwd><kwd>dressings</kwd><kwd>network meta-analysis</kwd><kwd>systematic review</kwd></kwd-group><support-group><funding-group><funding-statement>This study was supported by Peking University Evidence-Based Nursing Research Fund (XZJJ-2022-09).</funding-statement></funding-group></support-group><counts><fig-count count="4"/><table-count count="5"/><page-count count="13"/><word-count count="6807"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><label>1.</label><title>Introduction</title><p>Chinese National Renal Data System reported that there were currently about 985000 dialysis patients at the end of 2022, including 140,500 individuals undergoing peritoneal dialysis (PD) [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Peritoneal dialysis-related infections, such as peritonitis, tunnel infection, and exit-site infection, are still common complications in PD patients. Exit-site infection (ESI) is characterized by the presence of purulent discharge with or without skin erythema at the catheter-epidermal interface [<xref rid="CIT0001" ref-type="bibr">1</xref>]. ESI is closely linked to tunnel infection and peritonitis. If left untreated, ESI can lead to PD technical failure resulting in increased hospitalization and high mortality [<xref rid="CIT0002" ref-type="bibr">2</xref>]. An estimated 20% of all peritonitis cases are preceded by an exit site or tunnel infection, especially the infection caused by S. aureus or P. aeruginosa [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Approximately 15% of ESIs lead to catheter loss, due to either refractory ESI or concomitant peritonitis [<xref rid="CIT0004" ref-type="bibr">4</xref>]. The incidence of exit-site infection is closely related to preventive strategies, sanitary conditions, living habits, environment humidity, and population characteristics. The studies showed that the global exit-site infection rate ranges from 0.05 to 0.42/patient year [<xref rid="CIT0005" ref-type="bibr">5</xref>]. Risk factors for ESIs included inadequate exit site care, history of catheter-pulling injury, swimming, frequent change of exit-site caregivers, and mechanical stress on the exit site [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Although guidelines strictly regulated the exit-site care procedure, there was no recommendation regarding the use of appropriate dressings to prevent ESI [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>The types of dressings for exit site care include disinfection dressing, antibacterial dressing, antibiotic dressing, regular dressing, sterile gauze, or no particular dressings. The updated guideline for catheter related infection from International Society Peritoneal Dialysis (ISPD) suggested that a dressing covering the exit site was not mandatory after exit site care and topical antibiotic use (2D), and suggested daily topical application of antibiotic cream or ointment (mupirocin or gentamicin) to prevent catheter-related infection (1&#x02009;C) [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Considering the concern of antibiotic resistance, daily topical application of antibiotics must be reevaluated. A Cochrane study [<xref rid="CIT0008" ref-type="bibr">8</xref>] reported that the use of oral or topical antibiotic compared with placebo/no treatment, had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 191 patients, RR = 0.45, 95%CI 0.19&#x02009;&#x0223c;&#x02009;1.04) and the risk of peritonitis (5 studies, 395 patients, RR = 0.82, 95%CI 0.57&#x02009;&#x0223c;&#x02009;1.19). A multicenter cross-sectional survey from China also indicated that the application of antibacterial agents did not have any relationship with lower ESI [<xref rid="CIT0006" ref-type="bibr">6</xref>]. But there is no study to conclude and analysis the effect of different dressings without antibiotics in preventing ESI or peritonitis.</p><p>The selection of dressing should depend on the exit-site's characteristics, such as whether it's new or mature, infected or non-infected, draining or non-draining. Additionally, the choice of dressing may be influenced by a physician's expertise, the availability of the dressing at the moment, and the cost [<xref rid="CIT0009" ref-type="bibr">9</xref>]. An ideal exit-site dressing should prevent exit-site infections (ESIs), reduce healthcare cost and have few adverse effects. After the systematic review of exit-site dressings in 2003 by JBI, numerous studies have been conducted over the past 20&#x02009;years to explore the effects of different dressings in preventing ESI [<xref rid="CIT0010" ref-type="bibr">10</xref>]. However, they only compared the effects between two type dressings, not multiple dressings. Therefore, this study aims to conduct a systematic review and network meta-analysis to comprehensively evaluate their efficacy of various dressings in preventing ESI and peritonitis.</p></sec><sec sec-type="methods" disp-level="1" id="S0002"><label>2.</label><title>Methods</title><p>The protocol has been registered with the registration number CRD42022366756 at PROSPERO. This study is reported according to the Network Meta-Analysis extension of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-NMA) reporting guidelines [<xref rid="CIT0011" ref-type="bibr">11</xref>]. The PRISMA-NMA checklist is presented in <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Table S1</ext-link> (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix 1</ext-link>).</p><sec disp-level="2" id="S0002-S2001"><label>2.1.</label><title>Patient and public involvement</title><p>This meta-analysis included no patient or public involvement; hence, ethics approval and consent for participation were not required.</p></sec><sec disp-level="2" id="S0002-S2002"><label>2.2.</label><title>Literature search strategy</title><p>We searched PubMed, Embase, Web of science, CINAHL Plus with Full Text (EBSCO), Sino Med, Wan Fang Data, China National Knowledge Infrastructure (CNKI) from 1 January 1999 to 10 July 2023.The language restrictions were Chinese and English. The search terms used include four blocks of terms, including PD, dressing, ESI, peritonitis. The search strategy takes PubMed as an example (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix 3</ext-link>). We also supplemented the search by screening references from relevant systematic reviews and original studies.</p></sec><sec disp-level="2" id="S0002-S2003"><label>2.3.</label><title>Inclusion and exclusion criteria</title><p>The PICOS of the study design was shown in <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Table S2</ext-link> (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix 2</ext-link>). Randomized controlled trials, non-randomized controlled trials, and self-controlled trials were included in this study. Because there was a systematic review about the effect of antibiotics use on PD related infection [<xref rid="CIT0008" ref-type="bibr">8</xref>], the studies about antibiotic dressings are no longer included. The dressings for exit site care were divided into five categories, named sterile gauze, other non-antibacterial occlusive dressings (having no special antibacterial or disinfectant function, such as 3&#x02009;M wound dressings, hydrocolloid dressings, Mepilex dressings, IV3000 dressings, etc.), antibacterial dressings (having antibacterial effects, such as JUC Physical Antimicrobial Spray Dressings, polyallylamine spray, propolis, and dextran-curcumin filament cellulose hydrogel dressings, etc.), disinfectant dressing (having disinfection effects, such as Povidone-iodine ointment with a blocking dressing and chlorhexidine with sterile gauze, etc.), and no particular dressings (only cleansing the catheter exit site daily with non-disinfectant soap, 0.9% saline and/or povidone-iodine, without any other particular dressings).</p><p>The outcomes include ESI and peritonitis. ESI can be defined by symptom description [<xref rid="CIT0012" ref-type="bibr">12</xref>,<xref rid="CIT0013" ref-type="bibr">13</xref>] or scoring system [<xref rid="CIT0002" ref-type="bibr">2</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref>]. Peritonitis should be diagnosed when at least two of the following are present [<xref rid="CIT0015" ref-type="bibr">15</xref>]: &#x02460;clinical features: abdominal pain and/or cloudy dialysis effluent; &#x02461;dialysis effluent white cell count &#x0003e; 100/&#x000b5;L (after a dwell time of at least 2&#x02009;h), with &#x0003e; 50% polymorphonuclear leukocytes; &#x02462;positive dialysis effluent culture.</p><p>Studies that met any of the following criteria were excluded: the relevant data could not be extracted or converted from the original research (e.g. only showing a trend of change); the specific type of dressing used in the intervention was unclear; the study was reported in a language other than Chinese or English; the study was about topical antibiotics; the study was a repeat publication, review, or case report.</p><p>The screening and management of literature was performed using EndNote X8. Initially, two authors (FCY and LY) screened the titles and abstracts of the studies and then thoroughly read the full texts to determine their inclusion or exclusion based on the pre-determined criteria. If there were any discrepancies in the selection process, the corresponding author was consulted to resolve them.</p></sec><sec disp-level="2" id="S0002-S2004"><label>2.4.</label><title>Data extraction and quality evaluation</title><p>Two authors (FCY and JWY) independently extracted the data according to the Cochrane Handbook, including the following information: title, authors, publication year, study design, sample size, interventions and control measures (including dressings type, time, and frequency), outcome (the rate of ESI, peritonitis, and other complications) and other related results, such as cost, patients' experience, etc.</p><p>Three authors (FCY, JWY, and LY) evaluated the included literature independently according to the randomized controlled trial quality evaluation standards recommended in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The RoB 2 tool provides a framework for assessing the risk of bias in a single result (an estimate of the effect of an experimental intervention compared with a comparator intervention on a particular outcome) from any type of randomized trial [<xref rid="CIT0016" ref-type="bibr">16</xref>]. The evaluation indicators comprise seven items, including random sequence generation, allocation concealment, blinding patients and personnel, blinding of outcome assessors, incomplete outcome (i.e. withdrawals), selective outcome reporting, and other risks of bias. Each item was evaluated as 'low risk', 'high risk', or 'uncertain'. If there were any objections, it would be discussed or judged by the corresponding author.</p></sec><sec disp-level="2" id="S0002-S2005"><label>2.5.</label><title>Data synthesis and statistical analysis</title><p>This study used the frequency analysis method and random-effects model to conduct a network meta-analysis (NMA). Using pairwise and network meta-analysis, we estimated summary odds ratios (ORs) for dichotomous outcomes. Before performing the NMA, we evaluated the transitivity hypothesis. This assumption implies that studies comparing different interventions are similar enough to provide valid indirect inferences, and we try to ensure this by applying rigorous inclusion criteria. We did a statistical evaluation of consistency (i.e. the agreement between direct and indirect evidence) using the side-split approach and separating direct and indirect evidence. The loop-specific approach was applied to evaluate the loop consistency in the network structure. The surface under the cumulative ranking curve (SUCRA) value is the probability of each treatment being among the best of those in the network, with larger values representing higher ranking probabilities. The SUCRA value and cumulative ranking plots were used to calculate the ranking probabilities of each intervention. Heterogeneity in each pairwise comparison was assessed using inconsistency tests with the I<sup>2</sup> statistic (p value &#x0003e; 0.05 indicating consistency). The NMA was performed using Stata17.0. The adjusted funnel plot was created to qualitatively describe the risk of the small sample size effect.</p></sec></sec><sec sec-type="results" disp-level="1" id="S0003"><label>3.</label><title>Results</title><sec disp-level="2" id="S0003-S2001"><label>3.1.</label><title>Charatceristic of the include studies</title><p>After searching various databases, we identified 2092 potentially eligible studies. However, after removing duplicates, only 935 studies remained (<xref rid="t0001" ref-type="table">Table 1</xref>). We then read the titles and abstracts of these studies and identified 188 studies. Finally, after screening the full text of these 188 studies, we selected 13 studies for network analysis. Among these 13 studies, 6 were in Chinese [<xref rid="CIT0017" ref-type="bibr">17&#x02013;22</xref>] and 7 were in English [<xref rid="CIT0023" ref-type="bibr">23&#x02013;29</xref>]. The basic information of included studies are as <xref rid="t0002" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="t0001"><label>Table 1.</label><caption><p>PRISMA (preferred Reporting items for systematic reviews and meta-analyses) flow diagram of the selection process of the included studies.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><col width="80pt"/><tbody valign="top"><tr><td align="left">
<inline-graphic xlink:href="IRNF_A_2376331_ILG0001_B.jpg" content-type="black-white"/>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0002"><label>Table 2.</label><caption><p>Basic information of included studies.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">References</th><th align="center">Nation</th><th align="center">Publication year</th><th align="center">Study type</th><th align="center">Study group</th><th align="center">Control group</th><th align="center">Follow-up time</th><th align="center">Inclusion criteria</th><th align="center">Study group intervention</th><th align="center">Control group intervention</th><th align="center">Outcomes</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left">Mevlut Ceri [<xref rid="CIT0024" ref-type="bibr">24</xref>]</td><td rowspan="2" align="left">Turkey</td><td rowspan="2" align="char" char=".">2020</td><td rowspan="2" align="left">RCT</td><td rowspan="2" align="char" char=".">41</td><td rowspan="2" align="char" char=".">47</td><td align="left">555patients-months;</td><td rowspan="2" align="left">PD &#x0003e; 3months</td><td rowspan="2" align="left">Povidone&#x02013;iodine<xref rid="TF9" ref-type="table-fn"><sup>##</sup></xref></td><td rowspan="2" align="left" char=".">0.1%spray polyhexanide</td><td rowspan="2" align="left">ESI rate<xref rid="TF4" ref-type="table-fn"><sup>&#x0203b;</sup></xref>
<break/>Peritonitis rate<sup>&#x025b3;</sup><break/>Complications rate</td></tr><tr><td align="left">480patients-months</td></tr><tr><td align="left">Zhang Fengjie [<xref rid="CIT0017" ref-type="bibr">17</xref>]</td><td align="left">China</td><td align="char" char=".">2022</td><td align="left">Quasi-experimental study</td><td align="char" char=".">61</td><td align="char" char=".">61</td><td align="left">6months</td><td align="left">PD &#x0003e; 6&#x02009;months</td><td align="left">IV3000 dressing</td><td align="left">Sterile gauze</td><td align="left">ESI rate<sup>#.</sup><break/>Complications<break/>rate</td></tr><tr><td align="left">Zheng Yuanying [<xref rid="CIT0018" ref-type="bibr">18</xref>]</td><td align="left">China</td><td align="char" char=".">2017</td><td align="left">RCT</td><td align="char" char=".">30</td><td align="char" char=".">30</td><td align="left">6months</td><td align="left">after catheterization</td><td align="left">Hydrocolloid dressing</td><td align="left">Sterile gauze</td><td align="left">ESI rate<xref rid="TF5" ref-type="table-fn">*</xref>.<break/>intervals of dressing change</td></tr><tr><td align="left">Huang Hongmin [<xref rid="CIT0019" ref-type="bibr">19</xref>]</td><td align="left">China</td><td align="char" char=".">2013</td><td align="left">RCT</td><td align="char" char=".">30</td><td align="char" char=".">30</td><td align="left">12months</td><td align="left">NI</td><td align="left">Mepilex dressing</td><td align="left">Sterile gauze</td><td align="left">ESI rate<xref rid="TF3" ref-type="table-fn"><sup>&#x00026;</sup></xref></td></tr><tr><td align="left">Tang Aidang [<xref rid="CIT0020" ref-type="bibr">20</xref>]</td><td align="left">China</td><td align="char" char=".">2009</td><td align="left">Quasi-experimental study</td><td align="char" char=".">34</td><td align="char" char=".">32</td><td align="left">12months</td><td align="left">PD &#x0003e; 4&#x02009;weeks<break/>Without infections</td><td align="left">Hydrocolloid dressing</td><td align="left">Sterile gauze</td><td align="left">ESI rate<xref rid="TF3" ref-type="table-fn"><sup>&#x00026;</sup></xref></td></tr><tr><td align="left">Li Jing [<xref rid="CIT0021" ref-type="bibr">21</xref>]</td><td align="left">China</td><td align="char" char=".">2015</td><td align="left">Self-controlled trial</td><td align="char" char=".">104</td><td align="char" char=".">104</td><td align="left">12months</td><td align="left">Sterile gauze<break/>was used &#x0003e; 1year</td><td align="left">3M dressing</td><td align="left">Sterile gauze</td><td align="left">ESI rate<xref rid="TF3" ref-type="table-fn"><sup>&#x00026;</sup></xref></td></tr><tr><td align="left">Wang Jialin [<xref rid="CIT0022" ref-type="bibr">22</xref>]</td><td align="left">China</td><td align="char" char=".">2014</td><td align="left">Quasi-experimental study</td><td align="char" char=".">65</td><td align="char" char=".">65</td><td align="left">33months</td><td align="left">NI</td><td align="left">Mepilex dressing</td><td align="left">Sterile gauze</td><td align="left">ESI rate<sup>@</sup>Complications rate</td></tr><tr><td align="left">Luzar [<xref rid="CIT0023" ref-type="bibr">23</xref>]</td><td align="left">Belgium</td><td align="char" char=".">1989</td><td align="left">RCT</td><td align="char" char=".">74</td><td align="char" char=".">53</td><td align="left">1year</td><td align="left">2&#x02009;weeks after catheter<break/>implantation (85%)</td><td align="left">povidone iodine<break/>(concentration:20g/L) with sterile gauze</td><td align="left">cleansed the catheter exit site daily with<break/>nondisinfectant soap on sterile gauze.<xref rid="TF9" ref-type="table-fn"><sup>##</sup></xref></td><td align="left">ESI rate<sup>@</sup><break/>Peritonitis rate&#x025b3;</td></tr><tr><td align="left">M. N&#x000fa;&#x000f1;ez-Moral [<xref rid="CIT0029" ref-type="bibr">29</xref>]</td><td align="left">Spanish</td><td align="char" char=".">2014</td><td align="left">RCT</td><td align="char" char=".">30</td><td align="char" char=".">30</td><td align="left">12months</td><td align="left">Catheteriaztion &#x0003e; 6weeks</td><td align="left">polyhexanide solution</td><td align="left">traditional care with 0.9% saline and povidone-iodine<xref rid="TF9" ref-type="table-fn"><sup>##</sup></xref></td><td align="left">ESI rate<xref rid="TF4" ref-type="table-fn"><sup>&#x0203b;</sup></xref>
<break/>Peritonitis<sup>&#x025b3;</sup></td></tr><tr><td rowspan="2" align="left">Nancy M. Waite [<xref rid="CIT0025" ref-type="bibr">25</xref>]</td><td rowspan="2" align="left">Canada</td><td rowspan="2" align="char" char=".">1997</td><td rowspan="2" align="left">RCT</td><td rowspan="2" align="char" char=".">61</td><td rowspan="2" align="char" char=".">56</td><td align="left">14.6&#x02009;weeks</td><td rowspan="2" align="left">NI</td><td rowspan="2" align="left" char=".">3.5&#x02009;g of 10%<break/>povidone-iodine ointment</td><td rowspan="2" align="left">Sterile gauze</td><td rowspan="2" align="left">ESI rate<sup>@</sup><break/>Peritonitis rate<sup>&#x025b3;</sup><break/>S aureus Carrier rate</td></tr><tr><td align="left">13.2&#x02009;weeks</td></tr><tr><td align="left">Tam [<xref rid="CIT0026" ref-type="bibr">26</xref>]</td><td align="left">HongKong,<break/>China</td><td align="char" char=".">2014</td><td align="left">RCT</td><td align="char" char=".">37</td><td align="char" char=".">37</td><td align="left">6months</td><td align="left">Catheteriaztion &#x0003e; 3&#x02009;months</td><td align="left">JUCSpray dressing</td><td align="left">0.05% Chlorhexidine<break/>dressing</td><td align="left">ESI rate<xref rid="TF3" ref-type="table-fn"><sup>&#x00026;</sup></xref>
<break/>Complications rate</td></tr><tr><td align="left">Liu Haiyan [<xref rid="CIT0028" ref-type="bibr">28</xref>]</td><td align="left">China</td><td align="char" char=".">2021</td><td align="left">RCT</td><td align="char" char=".">27</td><td align="char" char=".">30</td><td align="left">11months</td><td align="left">5.74&#x02009;&#x000b1;&#x02009;3.19<break/>(years)</td><td align="left">Dex-Cur@SF hydrocolloid dressing</td><td align="left">Alginate aseptic wound dressing</td><td align="left">ESI rate<sup>@</sup><break/>Peritonitis Rate<sup>&#x025b3;</sup><break/>Readmission rate<break/>Patient satisfaction</td></tr><tr><td align="left">Lila Moghiseh [<xref rid="CIT0027" ref-type="bibr">27</xref>]</td><td align="left">Iran</td><td align="char" char=".">2022</td><td align="left">RCT</td><td align="char" char=".">30</td><td align="char" char=".">30</td><td align="left">6months</td><td align="left">PD &#x0003e; 3months</td><td align="left">10% propolis ointment&#x02009;+&#x02009;sterile gauze</td><td align="left">0.9% normal saline with sterile gauze</td><td align="left">ESI rate<xref rid="TF8" ref-type="table-fn"><sup>$</sup></xref>
<break/>Peritonitis<sup>&#x025b3;</sup></td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Explains:</p></fn><fn id="TF2"><p><bold><sup>#</sup></bold>Schafer exit-site score(ESS) [<xref rid="CIT0002" ref-type="bibr">2</xref>]: &#x02264;1 is classified as good condition; 2&#x02009;&#x0223c;&#x02009;3 is classified as suspicious infection. If there are purulent secretions, it can also diagnose infection; &#x02265;4 points is defined as infection.</p></fn><fn id="TF3"><p><sup>&#x00026;</sup>(1) Persistent redness and swelling greater than 13&#x02009;mm, or elevated granulation tissue at the exit site; (2) there is purulent or bloody discharge at the exit site; (3) pain, tenderness at the exit site or tunnel; (4) the secretion was positive for bacterial culture. If any of the aforementioned items are found, it could be diagnosed as ESI [<xref rid="CIT0015" ref-type="bibr">15</xref>].</p></fn><fn id="TF4"><p><sup>&#x0203b;</sup>An exit-site infection is defined by the presence of purulent drainage with or without erythema, edema, and tenderness, and the swabs obtained from the exit-site area were sent to a microbiology laboratory for evaluation [<xref rid="CIT0013" ref-type="bibr">13</xref>].</p></fn><fn id="TF5"><p>*Twardowski score system [<xref rid="CIT0038" ref-type="bibr">38</xref>]: exit site infection: The PD tube area had pain, redness, and swelling, with stiff skin and pus/blood drainage.</p></fn><fn id="TF6"><p>@ Clinical symptoms: Erythema, purulent exudation, bloody, or pain occur around the catheter.</p></fn><fn id="TF7"><p>&#x025b3;Peritonitis [<xref rid="CIT0007" ref-type="bibr">7</xref>]: Peritonitis is defined as a cloudy fluid and/or abdominal pain associated with a white blood cell count &#x02265;100/&#x003bc;L (with &#x0003e;50% neutrophils), and dialysate effluent was sent for microscopy and culture.</p></fn><fn id="TF8"><p><sup>$</sup>NI: no information.</p></fn><fn id="TF9"><p><sup>##</sup>Cleansed the catheter exit site daily with nondisinfectant soap on sterile gauze, traditional care with 0.9% saline and povidone-iodine, and only use povidone&#x02013;iodine was defined no particular dressingss.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2002"><label>3.2.</label><title>Quality assessment of included studies</title><p>The long-term exit-site caregiver are often patients themselves or their families, it is difficult to blind the participants. It is important to blind the exit-site evaluators for avoiding evaluation bias. Thus, we assessed the 'the evaluators were not blinded' in most studies as 'high risk'. The quality assessment results as <xref rid="F0001" ref-type="fig">Figure 1</xref>, there were 7 studies with high risk of bias [<xref rid="CIT0018" ref-type="bibr">18&#x02013;23</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref>], 3 studies with an unclear risk of bias [<xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>] and 3 studies at low risk [<xref rid="CIT0025" ref-type="bibr">25</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0029" ref-type="bibr">29</xref>]. We assessed the risk of publication bias in included trials visually using a funnel plot (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S2</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>).</p><fig position="float" id="F0001"><label>Figure 1.</label><caption><p>Bias risk of the included studies.</p></caption><graphic xlink:href="IRNF_A_2376331_F0001_C" content-type="color" position="float"/></fig></sec><sec disp-level="2" id="S0003-S2003"><label>3.3.</label><title>Results of network meta-analysis</title><sec disp-level="3" id="S0003-S2003-S3001"><label>3.3.1.</label><title>The effect of preventing exit-site infection</title><p>There were 13 studies [<xref rid="CIT0017" ref-type="bibr">17&#x02013;29</xref>] with 1229 participants of 5 types dressings included in this NMA study. Two studies are three-arm design [<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref>], only relevant data to this study were included. The result of NMA was shown in <xref rid="F0002" ref-type="fig">Figure 2a</xref>. The heterogeneity was low (I<sup>2</sup>=30.0%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.145, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S1</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>). It is widely believed that heterogeneity is small when I<sup>2</sup>&#x0003c;50%. And the loop-specific heterogeneity diagram was shown in <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S3</ext-link>. The results of side-split-approach on the direct comparison and indirect comparison were shown in <xref rid="t0003" ref-type="table">Table 3</xref>.</p><fig position="float" id="F0002"><label>Figure 2.</label><caption><p>(a) Network meta-analysis of eligible comparisons for preventing ESI. (b) The surface under the cumulative ranking curve (SUCRA) ranking chart for preventing ESI. ABD: antibacterial dressings; NAOD: non-antibacterial occlusive dressings; DD: disinfection dressings; NPD: no particular dressings; SG: sterile gauze.</p></caption><graphic xlink:href="IRNF_A_2376331_F0002_C" content-type="color" position="float"/></fig><table-wrap position="float" id="t0003"><label>Table 3.</label><caption><p>The comparisons between indirect and direct based on the side-split approach in preventing ESI.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Side</th><th align="center">Direct Coef.</th><th align="center">Std. Err.</th><th align="center">Indirect Coef.</th><th align="center">Std. Err.</th><th align="center">Difference Coef.</th><th align="center">Std. Err.</th><th align="center">P&#x0003e;|z|</th></tr></thead><tbody valign="top"><tr><td align="left">AB<break/>AD<break/>AE<break/>BC<break/>BD<break/>BE<break/>CD</td><td align="char" char=".">&#x02212;1.72<break/>0.34<break/>0.94<break/>1.97<break/>1.67<break/>0.94<break/>1.33</td><td align="char" char=".">0.88<break/>0.49<break/>0.38<break/>0.82<break/>1.60<break/>0.57<break/>0.29</td><td align="char" char=".">&#x02212;0.98<break/>2.20<break/>&#x02212;1.15<break/>&#x02212;0.16<break/>2.09<break/>3.05<break/>&#x02212;0.80</td><td align="char" char=".">0.63<break/>0.93<break/>0.83<break/>0.72<break/>0.67<break/>0.72<break/>1.05</td><td align="char" char=".">&#x02212;0.73<break/>&#x02212;1.85<break/>2.10<break/>2.14<break/>&#x02212;0.42<break/>&#x02212;2.10<break/>2.14</td><td align="char" char=".">1.08<break/>1.05<break/>0.92<break/>1.09<break/>1.74<break/>0.92<break/>1.09</td><td align="char" char=".">0.495<break/>0.078<break/>0.022<break/>0.051<break/>0.809<break/>0.022<break/>0.051</td></tr></tbody></table><table-wrap-foot><fn id="TF10"><p>Explain: A: disinfection dressings; B: antibacterial dressings; C: non-antibacterial occlusive dressings; D: sterile gauze; E:no particular dressings.</p></fn></table-wrap-foot></table-wrap><p>To prevent ESI, the head-to-head comparison in <xref rid="t0004" ref-type="table">Table 4</xref> (the forest figure was shown in <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S4</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>) demonstrated that antibacterial dressings were more effective than sterile gauze (OR:0.13, 95%CI 0.04&#x02009;&#x0223c;&#x02009;0.44), and no-particular dressings (OR:0.18, 95%CI 0.07&#x02009;&#x0223c;&#x02009;0.50); the non-antibacterial occlusive dressings were more effective than sterile gauze (OR:0.30, 95%CI 0.16&#x02009;&#x0223c;&#x02009;0.57). Among various types of dressings, antibacterial dressings (SUCRA = 97.6) had the highest probability of being the optimal dressings to prevent the exit site infection. The SUCRA ranking results were shown in <xref rid="F0002" ref-type="fig">Figure 2b</xref>: antibacterial dressings (SUCRA = 97.6) &#x0003e; non-antibacterial occlusive dressings (SUCRA = 68.3) &#x0003e; disinfection dressings (SUCRA = 50.6)&#x0003e; no-particular dressings (SUCRA = 23.9) &#x0003e;sterile gauze (SUCRA = 9.5). The network forest figure was shown in <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S4</ext-link>.</p><table-wrap position="float" id="t0004"><label>Table 4.</label><caption><p>Head-to-head comparison of different dressings for the prevention of ESI.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><tbody valign="top"><tr><td align="left">DD<break/>3.42(1.25,9.33)<break/>1.49(0.50,4.44)<break/>0.45(0.17,1.22)<break/>0.62(0.24,1.65)</td><td align="char" char=".">0.29(0.11,0.80)<break/>ABD<break/>0.44(0.13,1.45)<break/>0.13(0.04,0.44)<break/>0.18(0.07,0.50)</td><td align="char" char=".">0.67(0.23,2.00)<break/>2.30(0.69,7.63)<break/>NAOD<break/>0.30(0.16,0.57)<break/>0.42(0.10,1.69)</td><td align="char" char=".">2.21(0.82,5.97)<break/>7.55(2.29,24.86)<break/>3.29(1.77,6.13)<break/>SG<break/>1.38(0.35,5.40)</td><td align="char" char=".">1.60(0.61,4.23)<break/>5.47(2.01,14.86)<break/>2.38(0.59,9.58)<break/>0.72(0.19,2.83)<break/>NPD</td></tr></tbody></table><table-wrap-foot><fn id="TF11"><p>Explain: DD: disinfection dressings; ABD: antibacterial dressings; NAOD: non-antibacterial occlusive dressings; SG: sterile gauze; NPD: no particular dressings.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0005"><label>Table 5.</label><caption><p>Head-to-head comparison of different dressings for the prevention of mature ESI.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><tbody valign="top"><tr><td align="left">DD<break/>5.62(1.12,28.15)<break/>1.02(0.12,8.86)<break/>0.40(0.04,3.77)<break/>2.18(0.31,15.48)</td><td align="char" char=".">0.18(0.04,0.89)<break/>ABD<break/>0.18(0.04,0.77)<break/>0.07(0.01,0.34)<break/>0.39(0.13,1.19)</td><td align="char" char=".">0.98(0.11,8.55)<break/>5.52(1.30,23.43)<break/>NAOD<break/>0.39(0.17,0.90)<break/>2.14(0.34,13.31)</td><td align="char" char=".">2.52(0.27,24.02)<break/>14.20(2.94,68.65)<break/>2.57(1.12,5.93)<break/>SG<break/>5.49(0.79,37.99)</td><td align="char" char=".">0.46(0.06,3.27)<break/>2.58(0.84,7.93)<break/>0.47(0.08,2.91)<break/>0.18(0.03,1.26)<break/>NPD</td></tr></tbody></table><table-wrap-foot><fn id="TF12"><p>Explain: DD: disinfection dressings; ABD: antibacterial dressings; NAOD: non-antibacterial occlusive dressings; SG: sterile gauze; NPD: no particular dressings.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="3" id="S0003-S2003-S3002"><label>3.3.2.</label><title>Sensitivity analysis</title><p>The sensitivity analysis using the method of moving monomial studies found that Liu's study [<xref rid="CIT0028" ref-type="bibr">28</xref>] (antibacterial dressings vs non-antibacterial occlusive dressings) was the source of heterogeneity. Heterogeneity improved after this article was excluded (I<sup>2</sup>=28.9%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.162, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S6</ext-link>).</p><p>After comparing different types of dressings in sensitivity analysis (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S5</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>), the SUCRA results (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S9</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>) showed that non-antibacterial occlusive dressings had the highest score (SUCRA = 88.3), followed by antibacterial dressings (SUCRA = 82.9), disinfection dressings (SUCRA = 46.8), sterile gauze (SUCRA = 23.9), and no-particular dressings (SUCRA = 8.1).</p></sec><sec disp-level="3" id="S0003-S2003-S3003"><label>3.3.3.</label><title>The effect of preventing mature exit site infection</title><p>Mature exit site is defined as after the sinus epithelium has formed and completely healed, which usually 4-8&#x02009;weeks after surgery [<xref rid="CIT0014" ref-type="bibr">14</xref>]. Seven studies [<xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>,<xref rid="CIT0026" ref-type="bibr">26&#x02013;29</xref>] involving 669 PD patients with mature exit site examined the use of dressings to prevent catheter related infections. The results were summarized in <xref rid="F0003" ref-type="fig">Figure 3a</xref>. As shown in <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S10</ext-link> (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>), the homogeneity test shows that I<sup>2</sup>=51.7%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.053. The NMA included only antibacterial dressings, sterile gauze, and non-antibacterial occlusive dressings in a closed loop to prevent ESI. The loop-specific heterogeneity showed tau<sup>2</sup>&#x0003c;0.001(<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S11</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>). There was no heterogeneity between direct and indirect comparisons based on the side-split approach in sensitivity (<italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p><fig position="float" id="F0003"><label>Figure 3.</label><caption><p>(a) Network meta-analysis of eligible comparisons for preventing ESI in patinets with mature exit site. (b) The surface under the cumulative ranking curve (SUCRA) ranking chart for preventing ESI in patinets with mature exit site. ABD: antibacterial dressings; NAOD: non-antibacterial occlusive dressings; DD: disinfection dressings; NPD: no particular dressings; SG: sterile gauze.</p></caption><graphic xlink:href="IRNF_A_2376331_F0003_C" content-type="color" position="float"/></fig><p>The head-to-head comparison in <xref rid="t0005" ref-type="table">Table 5</xref> demonstrated that antibacterial dressings were more effective than disinfection dressings (OR = 0.18, 95%CI 0.04&#x02009;&#x0223c;&#x02009;0.89), non-antibacterial occlusive dressings (OR = 0.18, 95%CI 0.04&#x02009;&#x0223c;&#x02009;0.77) and sterile gauze (OR = 0.07, 95%CI 0.01&#x02009;&#x0223c;&#x02009;0.34). There was no statistically significant difference between the no particular dressings and other dressings in the prevention of mature ESI. As shown in <xref rid="F0003" ref-type="fig">Figure 3b</xref>, the results of SUCRA were antibacterial dressings (SUCRA = 98.1) &#x0003e; no-particular dressings (SUCRA = 64.5) &#x0003e;non-antibacterial occlusive dressings (SUCRA = 42.5)&#x0003e; disinfection dressings (SUCRA = 38.3) &#x0003e;sterile gauze (SUCRA = 6.6).</p></sec><sec disp-level="3" id="S0003-S2003-S3004"><label>3.3.4.</label><title>The effect of preventing peritonitis</title><p>A total of 509 individuals were included in six studies that reported peritonitis outcomes [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>,<xref rid="CIT0027" ref-type="bibr">27&#x02013;29</xref>]. Disinfection dressings (<italic toggle="yes">n</italic>&#x02009;=&#x02009;135), antibacterial dressings (<italic toggle="yes">n</italic>&#x02009;=&#x02009;134), non-antibacterial occlusive dressings (<italic toggle="yes">n</italic>&#x02009;=&#x02009;30), sterile gauze (<italic toggle="yes">n</italic>&#x02009;=&#x02009;83), and no-particular dressings (<italic toggle="yes">n</italic>&#x02009;=&#x02009;127) were compared. The result of NMA was shown in <xref rid="F0004" ref-type="fig">Figure 4a</xref>. The homogeneity test shows that I<sup>2</sup>=0, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.785(<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S13</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>). The NMA included only disinfection dressings, antibacterial dressings, sterile gauze, and no-particular dressings in a closed loop to prevent peritonitis (<ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Figure S14</ext-link>, <ext-link xlink:href="10.1080/0886022X.2024.2376331" ext-link-type="doi">Appendix</ext-link>). The loop-specific heterogeneity showed tau<sup>2</sup>&#x0003c;0.001. There is no statistical significance in the effectiveness of disinfection dressings, antibacterial dressings, non-antibacterial occlusive dressings, sterile gauze, or no-particular dressings in preventing peritonitis (<ext-link xlink:href="https://dx.doi.org/10.1080/0886022X.2024.2376331" ext-link-type="uri">Table S5</ext-link>).</p><fig position="float" id="F0004"><label>Figure 4.</label><caption><p>(a) Network meta-analysis of eligible comparisons for preventing peritonitis. (b) The surface under the cumulative ranking curve (SUCRA) ranking chart for preventing peritonitis. ABD: antibacterial dressings; NAOD: non-antibacterial occlusive dressings; DD: disinfection dressings; NPD: no particular dressings; SG: sterile gauze.</p></caption><graphic xlink:href="IRNF_A_2376331_F0004_C" content-type="color" position="float"/></fig><p>As shown in <xref rid="F0004" ref-type="fig">Figure 4b</xref>, the results of SUCRA were antibacterial dressings (SUCRA = 62.6) &#x0003e;non-antibacterial occlusive dressings (SUCRA = 57.4) &#x0003e;disinfection dressings (SUCRA = 53.1) &#x0003e;sterile gauze (SUCRA = 48.1)&#x0003e; no-particular dressings (SUCRA = 28.7).</p></sec></sec><sec disp-level="2" id="S0003-S2004"><label>3.4.</label><title>Descriptive analysis</title><sec disp-level="3" id="S0003-S2004-S3001"><label>3.4.1.</label><title>The adverse effects of different types of dressings</title><p>Among the 13 studies included, only five reported adverse reactions to dressings [<xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>,<xref rid="CIT0024" ref-type="bibr">24&#x02013;26</xref>]. Two of them found that non-antibacterial occlusive dressings had lower rates of adverse reactions compared to sterile gauze [<xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>]. Zhang Fengjie et&#x000a0;al. [<xref rid="CIT0017" ref-type="bibr">17</xref>] reported fewer cases of pruritus (0 vs 2 cases), erythema (0 vs 2 cases), and blisters (1 vs 4 cases) at the exit site using non-antibacterial occlusive dressings compared with sterile gauze. Wang Jialin et&#x000a0;al. [<xref rid="CIT0022" ref-type="bibr">22</xref>] reported nearly the same results, there were fewer cases of erythema (3 vs 6), pain (0 vs 7), dampness (3 vs 18), and burning sensation (6 vs 26) in the exit site using non-antibacterial occlusive dressings compared with sterile gauze.</p><p>Three literatures reported the adverse effects of antibacterial and disinfection dressings [<xref rid="CIT0024" ref-type="bibr">24&#x02013;26</xref>]. Only in the study of Mevlut Ceri et&#x000a0;al. [<xref rid="CIT0024" ref-type="bibr">24</xref>], a randomized controlled trial of 93 people, reported 2 cases of skin allergy caused by polyhexanide solution (a kind of antibacterial solution).</p></sec><sec disp-level="3" id="S0003-S2004-S3002"><label>3.4.2.</label><title>The cost of different types of dressings in preventing ESI</title><p>Tam et&#x000a0;al. [<xref rid="CIT0026" ref-type="bibr">26</xref>] reported that antibacterial spray dressings (JUC spray dressings) were cheaper (0.5 vs. 3 HK$) than disinfection dressings (0.05% chlorhexidine). Some studies stated that non-antibacterial occlusive dressings had 2 to 4 times longer dressing change interval than sterile gauze, which could help balance the higher cost of non-antibacterial occlusive dressings to some extent. Zheng Yuanying et&#x000a0;al. [<xref rid="CIT0018" ref-type="bibr">18</xref>] reported all 30 patients in the sterile gauze group changed the dressing within 72&#x02009;h, while only 8 patients in the hydrocolloid dressing group changed the dressing within 72&#x02009;h. Hongmin et&#x000a0;al. [<xref rid="CIT0019" ref-type="bibr">19</xref>] stated that sterile gauze would be changed 2-3 times a week if keeping dry, while non-antibacterial occlusive dressings, such as Mepilex, should be changed once every 5 to 7&#x02009;days if the exudate makes less than 1/2 of the dressings contamination.</p></sec></sec></sec><sec sec-type="discussion" disp-level="1" id="S0004"><label>4.</label><title>Discussion</title><p>This is the first systematic review and network-meta-analysis to comprehensively analysis the efficacy dressings for preventing ESI in peritoneal dialysis patients. In this NMA, we included 13 studies with 1229 participants. We compared the effectiveness of disinfection dressings, antibacterial dressings, non-antibacterial occlusive dressings, sterile gauze, and no-particular dressings in preventing exit site infection and peritonitis in PD patients. Compared with sterile gauze, the effect of most dressings in preventing exit site infection was statistically significant. Our NMA found that antibacterial dressings ranked first in preventing exit site infection compared with other interventions. No-particular dressings may be a best choice for preventing mature ESI. However, in terms of the effects for preventing peritonitis, there was no statistical significance among all five types of dressings.</p><sec disp-level="2" id="S0004-S2001"><label>4.1.</label><title>Antibacterial dressings may be a better choice for preventing ESI</title><p>This study found that antibacterial dressings have obvious advantages in the prevention of ESI. Antibacterial dressings include JUC Physical Antimicrobial Spray Dressings, polyallylamine spray, propolis, and dextran-curcumin filament cellulose hydrogel dressings, etc. Antibacterial dressings generally have the same anti-staphylococcus aureus, anaerobic bacteria and other effects as antibiotics. They have a high decontamination effect, and can counter the problem of drug resistance. Some studies have found that antibacterial honey can better inhibit Staphylococcus aureus [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0031" ref-type="bibr">31</xref>], the HONEYPOT study found that with standard catheter exit care, the incidence of catheter-related infections was similar between patients randomly receiving daily local antibacterial honey treatment and patients receiving mupirocin nasal ointment treatment [<xref rid="CIT0032" ref-type="bibr">32</xref>]. In addition, natural Chinese herbs with antibacterial effects have also brought us new sight, such as curcumin. But in the current study, it is combined with dextran, the effect of preventing ESI alone still needs further studies [<xref rid="CIT0028" ref-type="bibr">28</xref>]. The cost of antibacterial dressing may be cheaper than other dressings for preventing ESI as well. There is one research reported that the using polyhexanide is less expensive than performing the traditional approach with povidone-iodine [<xref rid="CIT0029" ref-type="bibr">29</xref>], and one research reported that JUC physical antimicrobial dressing are cheaper than chlorhexidine dressing [<xref rid="CIT0026" ref-type="bibr">26</xref>]. Although antibacterial dressings have lots of advantages, attention should be paid to adverse reaction.</p><p>Disinfectant dressings include povidone-iodine ointment with a blocking dressing and chlorhexidine with sterile gauze, etc. Although current studies have shown that disinfection dressings can reduce the infection of Staphylococcus aureus [<xref rid="CIT0025" ref-type="bibr">25</xref>,<xref rid="CIT0029" ref-type="bibr">29</xref>] to prevent ESI and peritonitis, the choice of disinfection dressings should be careful due to more adverse reactions. According to a study conducted by Htay et&#x000a0;al. [<xref rid="CIT0033" ref-type="bibr">33</xref>], 12% of patients developed contact dermatitis after using chlorhexidine-impregnated sponge dressing for a year. This may have been related to a longer duration of exposure to chlorhexidine gluconate in PD patients. It should be noticed that povidone-iodine ointment cannot be used in patients who are allergic to iodine. It is also recommended to monitor the thyroid function of patients who use it for a long time [<xref rid="CIT0023" ref-type="bibr">23</xref>].</p></sec><sec disp-level="2" id="S0004-S2002"><label>4.2.</label><title>No-particular dressings may be a better choice for preventing mature ESI</title><p>Although the SUCRA suggested that antibacterial dressings are better than others in preventing mature ESI, we noticed that there is no statistical significance between no-particular dressings and other dressings. Some RCTs showed that patients who used a routine cleaning procedure with a dressing over the exit site had no significant difference in the number of infections compared to those using the same procedure but who left the exit site open [<xref rid="CIT0034" ref-type="bibr">34</xref>]. This is the same as the results of this study. And a pilot study found that the absence of P. aeruginosa ESI and no increased risk of developing S. aureus ESI in the non-dressing group as compared to the dressing group [<xref rid="CIT0035" ref-type="bibr">35</xref>]. This may be interpreted as a covered dressing does not provide an inhibitory effect on micro-organism growth but, conversely, provides a milieu for accelerated bacterial growth [<xref rid="CIT0035" ref-type="bibr">35</xref>].</p><p>Considering the costs of dressings, to choose no-particular dressing may become the choice for more peritoneal dialysis patients in the future. This conclusion goes in the same direction as the guidelines [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p></sec><sec disp-level="2" id="S0004-S2003"><label>4.3.</label><title>The choice of dressings should consider the clinical situation</title><p>Because sterile gauze costs less and are more versatile, they still dominate the medical market [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Even though the frequency of dressing change is higher, and the effect of preventing ESI is not as good as other dressings, the sterile gauze is more cost-effective for early more exudative exit site which require frequently dressing change. A cohort study claimed that suggests that a nurse should change the initial dressing after the first week following catheter insertion, independently of dressing type used [<xref rid="CIT0037" ref-type="bibr">37</xref>]. The ideal dressings for new exit-site are uncertain. New exit sites can be categorized into four types [<xref rid="CIT0038" ref-type="bibr">38</xref>]: fast-healing exits; slow-healing exits without infection; healing interrupted by infection initially looked identical to the fast-healing exit, but within 6&#x02009;weeks the epidermis did not progress or regress; slow-healing exits due to early infection, granulation tissue became soft or fleshy and/or drainage became purulent by 2-3&#x02009;weeks. Therefore, the selection of new exit-site dressing should according to the different clinical situations.</p><p>The longer the interval between dressing changes at the exit-site, the lower the rate of bacterial culture [<xref rid="CIT0039" ref-type="bibr">39</xref>]. The literature included in this study showed that the dressing change interval for non-antibacterial occlusive dressings is 2-4 times longer than that of sterile gauze [<xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>]. Considering non-antibacterial occlusive dressings often cost more than sterile gauze, they may be better for less exudative exit-site in non-humid area. It is important to note that non-antibacterial occlusive dressings can cause adverse reactions such as allergies due to different materials [<xref rid="CIT0040" ref-type="bibr">40</xref>]. More research is required to determine the most appropriate dressing or whether no-particular dressing should be used for different stages of the exit site.</p></sec><sec disp-level="2" id="S0004-S2004"><label>4.4.</label><title>No one dressing has been found to be superior in preventing peritonitis</title><p>This study found there is no one dressing was superior in preventing peritonitis. A study reported that polyhexanide group and the mupirocin had the same incidence in peritonitis [<xref rid="CIT0041" ref-type="bibr">41</xref>]. This study is similar to the previous results, perhaps due to the less incidence of peritonitis in the included literature or the short follow-up time, the statistical results of the five dressings in this study did not have statistical significance. Additionally, microbial biofilm is universal in PD catheters with the subclinical menace of Staphylococci and P. aeruginosa [<xref rid="CIT0042" ref-type="bibr">42</xref>], which is also a risk factor for peritonitis while dressings may not affect them. Although microorganisms may access the peritoneum through the catheter exit-site and tunnel, the association between peritonitis and catheter ESI was described in just less than 13% of all peritonitis episodes [<xref rid="CIT0043" ref-type="bibr">43</xref>]. It is not clear to claim the relationship between ESI and peritonitis, more rigorous randomized controlled studies with larger samples are needed to explore the effect of exit site care for preventing peritonitis.</p></sec></sec><sec disp-level="1" id="S0005"><label>5.</label><title>Limitations</title><p>It's important to note that the study has some limitations. Firstly, due to the limited number of original studies, we cannot accurate to conclude that one dressing is superior than the other, such as hydrocolloid dressings and 3&#x02009;M wound dressings. Additionally, dressings produced by different manufacturers may have slightly different compositions, which was not considered. Secondly, other factors such as dialysis duration and history of infection at the exit site were not analyzed, which could have contributed to the heterogeneity between studies. Thirdly, the ESI definition was various in different studies, thus the information bias may exist. Fourth, categorization of early exit site and mature exit site was not completed due to less information provided in some included literature to provide recommendations for the selection of dressings for early exit site care. Fifth, the literature included in this study spanned a wide range of publication time, and the quality of the literature included studies was relatively low. Sixth, we defined dressings with disinfectant as disinfection dressings, it is unclear if the overall reduction of exit-site infection was due to dressing or disinfectant or their synergism. Seventh, the language of the selected studies was only restricted to Chinese and English, which is a potential bias. Most of the studies included in this meta-analysis were originated from China (8/13) and the rest is coming from non-tropical area. Therefore, the results of this study may not be applicable to humid tropical countries. Furthermore, the selected studies included quasi-experimental studies and before-after studies in addition to randomized controlled studies, which may be the source of the heterogeneity of this paper. Therefore, further high-quality randomized controlled trials are needed to support and supplement these conclusions.</p></sec><sec sec-type="conclusions" disp-level="1" id="S0006"><label>6.</label><title>Conclusion</title><p>Overall, antibacterial dressings may be superior in preventing exit-site infection compared with disinfection dressings, non-antibacterial occlusive dressings, sterile gauze, and no-particular dressings. This may be due to its not only provides a wet environment conducive to wound growth and reduces the number of dressing changes, but also has antibacterial effect. However, no one dressing has been found to be superior in preventing peritonitis. Therefore, the patient's individual circumstances, the stage of the exit site, the adverse reactions of the dressing, and the cost should be considered when select an appropriate dressing for PD patients' exit site care. No one dressing is strongly recommended for preventing exit site infection or peritonitis. More rigorous scientific studies are still needed to explore the effect of using different dressings to prevent exit site infection and peritonitis, in order to provide more evidence-based choices for exit site care in PD patients.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM5667" position="float" content-type="local-data"><caption><title>Supplemental Material</title></caption><media xlink:href="IRNF_A_2376331_SM5667.pdf"/></supplementary-material><supplementary-material id="SM0465" position="float" content-type="local-data"><caption><title>TheAppecdix.docx</title></caption><media xlink:href="IRNF_A_2376331_SM0465.docx"/></supplementary-material><supplementary-material id="SM0464" position="float" content-type="local-data"><caption><title>Figures.docx</title></caption><media xlink:href="IRNF_A_2376331_SM0464.docx"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful for the support of Peking University Evidence-Based Nursing Research Fund.</p></ack><sec disp-level="1" id="S0007"><title>Authors' contributions</title><p>F CY and LY contributed to the conception and design of the study, literature search, data extraction, risk of bias assessment, data analysis, and drafting of the manuscript. J WY made significant contributions to the conception and design of the literature search and risk of bias assessment. L MY contributed to drafting of the manuscript. S CY, as the corresponding author, made substantial contributions to the conception and design, literature search and critically important intellectual content revisions of the manuscript. All authors have read and approved the final version of the manuscript and agree with the order of the authors' presentation.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0008"><title>Disclosure statement</title><p>The authors declared no conflicts of interest in any part of the study.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen Xiaojun</surname>
<given-names>LH</given-names></string-name>, <string-name><surname>Xinju</surname>
<given-names>Z</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Investigation and analyses on the peritoneal dialysis fees and reimbursement from medical insurance in Chinese mainland</article-title>. <source>Chin J Blood Purificat</source>. <year>2023</year>;<volume>22</volume>(<issue>05</issue>):<fpage>321</fpage>&#x02013;<lpage>326</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szeto</surname>
<given-names>C-C</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>PK-T</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>DW</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>ISPD catheter-related infection recommendations: 2017 &#x000ad;update</article-title>. <source>Perit Dial Int</source>. <year>2017</year>;<volume>37</volume>(<issue>2</issue>):<fpage>141</fpage>&#x02013;<lpage>154</lpage>. doi: <pub-id pub-id-type="doi">10.3747/pdi.2016.00120</pub-id>.<pub-id pub-id-type="pmid">28360365</pub-id>
</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Au</surname>
<given-names>CWH</given-names></string-name>, <string-name><surname>Yap</surname>
<given-names>DYH</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>JFW</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exit site infection and peritonitis due to Serratia species in patients &#x000ad;receiving peritoneal dialysis: epidemiology and clinical outcomes</article-title>. <source>Nephrology (Carlton)</source>. <year>2021</year>;<volume>26</volume>(<issue>3</issue>):<fpage>255</fpage>&#x02013;<lpage>261</lpage>. doi: <pub-id pub-id-type="doi">10.1111/nep.13813</pub-id>.<pub-id pub-id-type="pmid">33150699</pub-id>
</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burkhalter</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Clemenger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Haddoub</surname>
<given-names>SS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pseudomonas exit-site infection: treatment outcomes with topical gentamicin in addition to systemic antibiotics</article-title>. <source>Clin Kidney J</source>. <year>2015</year>;<volume>8</volume>(<issue>6</issue>):<fpage>781</fpage>&#x02013;<lpage>784</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ckj/sfv089</pub-id>.<pub-id pub-id-type="pmid">26613039</pub-id>
</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sachar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shah</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Epidemiology, management, and prevention of exit site infections in peritoneal dialysis patients</article-title>. <source>Ther Apher Dial</source>. <year>2022</year>;<volume>26</volume>(<issue>2</issue>):<fpage>275</fpage>&#x02013;<lpage>287</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1744-9987.13726</pub-id>.<pub-id pub-id-type="pmid">34435734</pub-id>
</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ding</surname>
<given-names>X-R</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>H-E</given-names></string-name>, <string-name><surname>Liao</surname>
<given-names>Y-M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Daily self-care practices influence exit-site condition in patients having peritoneal dialysis: a multicenter cross-sectional survey</article-title>. <source>J Adv Nurs</source>. <year>2021</year>;<volume>77</volume>(<issue>5</issue>):<fpage>2293</fpage>&#x02013;<lpage>2306</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jan.14751</pub-id>.<pub-id pub-id-type="pmid">33432661</pub-id>
</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chow</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>PK-T</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>ISPD Catheter-related Infection Recommendations: 2023 Update</article-title>. <source>Perit Dial Int</source>. <year>2023</year>;<volume>43</volume>(<issue>3</issue>):<fpage>201</fpage>&#x02013;<lpage>219</lpage>. doi: <pub-id pub-id-type="doi">10.1177/08968608231172740</pub-id>.<pub-id pub-id-type="pmid">37232412</pub-id>
</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Campbell</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Mudge</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Craig</surname>
<given-names>JC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antimicrobial agents for preventing peritonitis in peritoneal dialysis &#x000ad;patients</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2017</year>;<volume>4</volume>(<issue>4</issue>):<fpage>Cd004679</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD004679.pub3</pub-id>.<pub-id pub-id-type="pmid">28390069</pub-id>
</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Obagi</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Damiani</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Grada</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Principles of wound dressings: a review</article-title>. <source>Surg Technol Int</source>. <year>2019</year>;<volume>35</volume>:<fpage>50</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">31480092</pub-id>
</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lockwood</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hodgkinson</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Page</surname>
<given-names>T.</given-names></string-name></person-group>
<article-title>Clinical effectiveness of different approaches to peritoneal dialysis catheter exit-site care</article-title>. <source>JBI Libr Syst Rev</source>. <year>2003</year>;<volume>1</volume>(<issue>5</issue>):<fpage>1</fpage>&#x02013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.11124/jbisrir-2003-381</pub-id>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hutton</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Salanti</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Caldwell</surname>
<given-names>DM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The PRISMA &#x000ad;extension statement for reporting of systematic reviews incorporating network meta-analyses of health care &#x000ad;interventions: checklist and explanations</article-title>. <source>Ann Intern Med</source>. <year>2015</year>;<volume>162</volume>(<issue>11</issue>):<fpage>777</fpage>&#x02013;<lpage>784</lpage>. doi: <pub-id pub-id-type="doi">10.7326/M14-2385</pub-id>.<pub-id pub-id-type="pmid">26030634</pub-id>
</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>PK-T</given-names></string-name>, <string-name><surname>Szeto</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Piraino</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Peritoneal dialysis-related infections recommendations: 2010 &#x000ad;update</article-title>. <source>Perit Dial Int</source>. <year>2010</year>;<volume>30</volume>(<issue>4</issue>):<fpage>393</fpage>&#x02013;<lpage>423</lpage>. doi: <pub-id pub-id-type="doi">10.3747/pdi.2010.00049</pub-id>.<pub-id pub-id-type="pmid">20628102</pub-id>
</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Xiangmei</surname>
<given-names>C.</given-names></string-name></person-group>
<source>Peritoneal Dialysis Standard Operating Procedure (SOP)</source>. <publisher-loc>Beijing</publisher-loc>: <publisher-name>People's Medical Officer Press</publisher-name>; <year>2011</year>.</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qingwen</surname>
<given-names>W.</given-names></string-name></person-group>
<article-title>The prevention, diagnosis, and therapy of peritoneal dialysis catheter exit-site</article-title>. <source>Chin J Nephrol Dialy Transplant</source>. <year>1993</year>;<volume>02</volume>:<fpage>186</fpage>&#x02013;<lpage>189</lpage>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>PK-T</given-names></string-name>, <string-name><surname>Chow</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment</article-title>. <source>Perit Dial Int</source>. <year>2022</year>;<volume>42</volume>(<issue>2</issue>):<fpage>110</fpage>&#x02013;<lpage>153</lpage>. doi: <pub-id pub-id-type="doi">10.1177/08968608221080586</pub-id>.<pub-id pub-id-type="pmid">35264029</pub-id>
</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Higgins</surname>
<given-names>JPT</given-names></string-name>, <string-name><surname>Altman</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>G&#x000f8;tzsche</surname>
<given-names>PC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</article-title>. <source>BMJ</source>. <year>2011</year>;<volume>343</volume>(<issue>oct18 2</issue>):<fpage>d5928</fpage>&#x02013;<lpage>d5928</lpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.d5928</pub-id>.<pub-id pub-id-type="pmid">22008217</pub-id>
</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang Fengjie</surname>
<given-names>CQ.</given-names></string-name></person-group>
<article-title>Effect of IV3000 dressing application at the catheter outlet on patients undergoing peritoneal dialysis</article-title>. <source>Henan Med Res</source>. <year>2022</year>;<volume>17</volume>(<issue>33</issue>):<fpage>3235</fpage>&#x02013;<lpage>3237</lpage>.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhwng Yuanying</surname>
<given-names>ZW.</given-names></string-name></person-group>
<article-title>Observation of the effects of hydrocolloid dressing on exit wound of peritoneal dialysis catheter</article-title>. <source>J Wan Med Coll</source>. <year>2017</year>;<volume>36</volume>(<issue>06</issue>):<fpage>604</fpage>&#x02013;<lpage>606</lpage>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hongmin</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>The study of Mepliex dressings in preventing peritoneal dialysis catheter exit-site infection</article-title>. <source>J Nurs Train</source>. <year>2013</year>;<volume>28</volume>(<issue>04</issue>):<fpage>362</fpage>&#x02013;<lpage>363</lpage>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang AIdang</surname>
<given-names>ZD</given-names></string-name>, <string-name><surname>Qingyun</surname>
<given-names>Z.</given-names></string-name></person-group>
<article-title>The effect of hydrocolloid dressings in preventing peritoneal dialysis exit-site &#x000ad;infection</article-title>. <source>J Nurs Sci (Chin)</source>. <year>2009</year>;<volume>16</volume>(<issue>21</issue>):<fpage>66</fpage>&#x02013;<lpage>67</lpage>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li Jing</surname>
<given-names>ZS</given-names></string-name>, <string-name><surname>Xiujuan</surname>
<given-names>HE</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The effect of 3M woung dressings in peritoneal dialysis exit-site infection</article-title>. <source>Shenz J Integr Tradit Chin West Med</source>. <year>2015</year>;<volume>25</volume>(<issue>08</issue>):<fpage>20</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jinggang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Min</surname>
<given-names>Z</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Clinical research of mepilex dressing on preventing infection in catheter opening for peritoneal dialysis</article-title>. <source>Chin J Nosocomiol</source>. <year>2014</year>;<volume>24</volume>(<issue>15</issue>):<fpage>3761</fpage>&#x02013;<lpage>3763</lpage>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luzar</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Balf</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial</article-title>. <source>Perit Dial Int</source>. <year>1990</year>;<volume>10</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">2085577</pub-id>
</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ceri</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yilmaz</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Unverdi</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Effect of local polyhexanide application in preventing exit-site infection and peritonitis: a randomized controlled trial</article-title>. <source>Ther Apher Dial</source>. <year>2020</year>;<volume>24</volume>(<issue>1</issue>):<fpage>81</fpage>&#x02013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1744-9987.12836</pub-id>.<pub-id pub-id-type="pmid">31066988</pub-id>
</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waite</surname>
<given-names>NM</given-names></string-name>, <string-name><surname>Webster</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Laurel</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections</article-title>. <source>Am J Kidney Dis</source>. <year>1997</year>;<volume>29</volume>(<issue>5</issue>):<fpage>763</fpage>&#x02013;<lpage>768</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0272-6386(97)91130-6</pub-id>.<pub-id pub-id-type="pmid">9159313</pub-id>
</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tam</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>Chow</surname>
<given-names>SK.</given-names></string-name></person-group>
<article-title>A preliminary report on the effectiveness of nanotechnology anti-microbial spray dressing in preventing Tenckhoff catheter exit-site infection</article-title>. <source>Perit Dial Int</source>. <year>2014</year>;<volume>34</volume>(<issue>6</issue>):<fpage>670</fpage>&#x02013;<lpage>673</lpage>. doi: <pub-id pub-id-type="doi">10.3747/pdi.2013.00199</pub-id>.<pub-id pub-id-type="pmid">25228219</pub-id>
</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moghiseh</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Nobahar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ghorbani</surname>
<given-names>R</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The impact of Propolis on catheter exit site infection and peritonitis in peritoneal Dialysis patients: a clinical trial</article-title>. <source>BMC Nephrol</source>. <year>2022</year>;<volume>23</volume>(<issue>1</issue>):<fpage>408</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12882-022-03036-7</pub-id>.<pub-id pub-id-type="pmid">36564743</pub-id>
</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>X.</given-names></string-name></person-group>
<article-title>Early nursing care of peritoneal dialysis catheter outlet with multi-functional nanogel of antibacterial and healing</article-title>. <source>Mat Express</source>. <year>2021</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1412</fpage>&#x02013;<lpage>1419</lpage>. doi: <pub-id pub-id-type="doi">10.1166/mex.2021.2047</pub-id>.</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>N&#x000fa;&#x000f1;ez-Moral</surname>
<given-names>M</given-names></string-name>, <string-name><surname>S&#x000e1;nchez-&#x000c1;lvarez</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gonz&#x000e1;lez-D&#x000ed;az</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. Results of a prospective randomized trial</article-title>. <source>Perit Dial Int</source>. <year>2014</year>;<volume>34</volume>(<issue>3</issue>):<fpage>271</fpage>&#x02013;<lpage>277</lpage>. doi: <pub-id pub-id-type="doi">10.3747/pdi.2012.00109</pub-id>.<pub-id pub-id-type="pmid">24497599</pub-id>
</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Badve</surname>
<given-names>SV</given-names></string-name>, <string-name><surname>Pascoe</surname>
<given-names>EM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial</article-title>. <source>Perit Dial Int</source>. <year>2015</year>;<volume>35</volume>(<issue>7</issue>):<fpage>712</fpage>&#x02013;<lpage>721</lpage>. doi: <pub-id pub-id-type="doi">10.3747/pdi.2014.00206</pub-id>.<pub-id pub-id-type="pmid">26224790</pub-id>
</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Edet</surname>
<given-names>UO</given-names></string-name>, <string-name><surname>Mbim</surname>
<given-names>EN</given-names></string-name>, <string-name><surname>Ezeani</surname>
<given-names>E</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antimicrobial analysis of honey against Staphylococcus aureus isolates from wound, ADMET properties of its bioactive compounds and in-silico evaluation against dihydropteroate synthase</article-title>. <source>BMC Complement Med Ther</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>39</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12906-023-03841-z</pub-id>.<pub-id pub-id-type="pmid">36747234</pub-id>
</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Badve</surname>
<given-names>SV</given-names></string-name>, <string-name><surname>Pascoe</surname>
<given-names>EM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial</article-title>. <source>Lancet Infect Dis</source>. <year>2014</year>;<volume>14</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70258-5</pub-id>.<pub-id pub-id-type="pmid">24119840</pub-id>
</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Htay</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Choo</surname>
<given-names>JCJ</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>DW</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chlorhexidine-impregnated sponge dressing for prevention of catheter exit-site infection in peritoneal dialysis patients: a pilot study</article-title>. <source>Int Urol Nephrol</source>. <year>2021</year>;<volume>53</volume>(<issue>4</issue>):<fpage>803</fpage>&#x02013;<lpage>812</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11255-020-02674-w</pub-id>.<pub-id pub-id-type="pmid">33025409</pub-id>
</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naylor</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Roe</surname>
<given-names>B.</given-names></string-name></person-group>
<article-title>A study of the efficacy of dressings in preventing infections of continuous ambulatory peritoneal dialysis catheter exit sites</article-title>. <source>J Clin Nurs</source>. <year>1997</year>;<volume>6</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2702.1997.tb00279.x</pub-id>.<pub-id pub-id-type="pmid">9052106</pub-id>
</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mushahar</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Mei</surname>
<given-names>LW</given-names></string-name>, <string-name><surname>Yusuf</surname>
<given-names>WS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exit-site dressing and infection in peritoneal dialysis: a randomized controlled pilot trial</article-title>. <source>Perit Dial Int</source>. <year>2016</year>;<volume>36</volume>(<issue>2</issue>):<fpage>135</fpage>&#x02013;<lpage>139</lpage>. doi: <pub-id pub-id-type="doi">10.3747/pdi.2014.00195</pub-id>.<pub-id pub-id-type="pmid">26374836</pub-id>
</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindholm</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Searle</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Wound management for the 21st century: combining effectiveness and efficiency</article-title>. <source>Int Wound J</source>. <year>2016</year>;<volume>13 Suppl 2</volume>(<issue>Suppl 2</issue>):<fpage>5</fpage>&#x02013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1111/iwj.12623</pub-id>.</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Figueiredo</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>de Mattos</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Saraiva</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Comparison between types of dressing following catheter insertion and early exit-site infection in peritoneal dialysis</article-title>. <source>J Clin Nurs</source>. <year>2017</year>;<volume>26</volume>(<issue>21-22</issue>):<fpage>3658</fpage>&#x02013;<lpage>3663</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jocn.13738</pub-id>.<pub-id pub-id-type="pmid">28122398</pub-id>
</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Twardowski</surname>
<given-names>ZJ</given-names></string-name>, <string-name><surname>Prowant</surname>
<given-names>BF.</given-names></string-name></person-group>
<article-title>Exit-site healing post catheter implantation</article-title>. <source>Perit Dial Int</source>. <year>1996</year>;<volume>16 Suppl 3</volume>(<issue>3_suppl</issue>):<fpage>S51</fpage>&#x02013;<lpage>s70</lpage>. doi: <pub-id pub-id-type="doi">10.1177/089686089601603S03</pub-id>.<pub-id pub-id-type="pmid">8860150</pub-id>
</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tanaka</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yosizawa</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sakuma</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Keeping the catheter exit site clean by sealing with a dressing film in patients under continuous ambulatory peritoneal dialysis</article-title>. <source>Adv Perit Dial</source>. <year>2002</year>;<volume>18</volume>:<fpage>158</fpage>&#x02013;<lpage>160</lpage>.<pub-id pub-id-type="pmid">12402610</pub-id>
</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Broussard</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Powers</surname>
<given-names>JG.</given-names></string-name></person-group>
<article-title>Wound dressings: selecting the most appropriate type</article-title>. <source>Am J Clin Dermatol</source>. <year>2013</year>;<volume>14</volume>(<issue>6</issue>):<fpage>449</fpage>&#x02013;<lpage>459</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40257-013-0046-4</pub-id>.<pub-id pub-id-type="pmid">24062083</pub-id>
</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Findlay</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Serrano</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Punzalan</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Increased peritoneal dialysis exit site infections using topical antiseptic polyhexamethylene biguanide compared to mupirocin: results of a safety interim analysis of an open-label prospective randomized study</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>(<issue>5</issue>):<fpage>2026</fpage>&#x02013;<lpage>2028</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.02079-12</pub-id>.<pub-id pub-id-type="pmid">23403425</pub-id>
</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sampaio</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Machado</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Gomes</surname>
<given-names>AM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Deciphering the contribution of biofilm to the pathogenesis of peritoneal dialysis infections: characterization and microbial behaviour on dialysis fluids</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>6</issue>):<fpage>e0157870</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0157870</pub-id>.<pub-id pub-id-type="pmid">27336367</pub-id>
</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Diepen</surname>
<given-names>AT</given-names></string-name>, <string-name><surname>Tomlinson</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Jassal</surname>
<given-names>SV.</given-names></string-name></person-group>
<article-title>The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2012</year>;<volume>7</volume>(<issue>8</issue>):<fpage>1266</fpage>&#x02013;<lpage>1271</lpage>. doi: <pub-id pub-id-type="doi">10.2215/CJN.00980112</pub-id>.<pub-id pub-id-type="pmid">22745277</pub-id>
</mixed-citation></ref></ref-list></back></article>